By Andrew Mann, M.D., Chief Medical Officer, Gosnold Behavioral Health
As addiction and mental health professionals, we continue to monitor emerging substances that may pose serious risks to individuals, families, and communities. One growing concern is 7-OH kratom. The term generally refers to products containing 7-hydroxymitragynine, or 7-OH, a potent compound associated with the kratom plant. While 7- OH occurs naturally in kratom in trace amounts, concentrated or enhanced 7-OH kratom products can contain much higher levels and may carry significant health risks.
Why 7-OH Kratom Is Concerning
The U.S. Food and Drug Administration (FDA) has warned consumers to avoid concentrated 7-OH products, including tablets, gummies, drink mixes, and shots that may be sold online and in smoke shops, gas stations, and convenience stores. These 7-OH kratom products have not been proven safe or effective for medical use and are not FDAapproved drugs. Because 7-OH acts on opioid receptors in the brain, repeated use may lead to tolerance, physical dependence, addiction, and withdrawal.
It is important to distinguish concentrated 7-OH kratom products from traditional kratom leaf. The FDA has specifically raised concern about products with added or enhanced levels of 7-OH. Consumers may not realize that products marketed as “enhanced,” “spiked,” or high-potency kratom can be very different from naturally occurring kratom leaf and may expose them to much higher concentrations of 7-OH.
A New Warning in Massachusetts
Massachusetts recently took additional action on kratom. Effective August 28, 2026, the Massachusetts Department of Public Health temporarily placed all forms of kratom, including 7-OH, into Schedule I under state law for up to one year. State officials cited concerns about largely unregulated products, variable potency and ingredients, opioid-like effects, and the potential for dependence and withdrawal.
Mental Health, Addiction, and Recovery
Some people may turn to 7-OH kratom while trying to manage pain, anxiety, depression, opioid withdrawal, or other concerns. Self-treating with an unregulated or highly concentrated product can create additional risks and may delay access to evidence-based care. Anyone experiencing mental health symptoms or substance use concerns should speak with a qualified healthcare professional.
The most important message is that addiction is treatable and recovery is possible. At Gosnold Behavioral Health, our mission is to excel in addiction and mental health treatment, to serve individuals and families affected by these illnesses, and to promote lasting recovery. Education about emerging substances such as 7-OH kratom is an important part of helping our communities recognize risks and know when to seek help.
What Patients and Families Should Know
The FDA recommends avoiding concentrated 7-OH products. If you or someone you know is using 7-OH kratom or is concerned about dependence, withdrawal, addiction, or mental health symptoms, contact a healthcare professional or addiction treatment provider. Anyone experiencing a severe reaction, difficulty breathing, loss of consciousness, or another medical emergency should call 911 immediately
Sources: U.S. Food and Drug Administration (FDA); Massachusetts Department of Public Health, 105 CMR 726.00 and August 28, 2026 kratom public health guidance.